Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Express Scripts
Boehringer Ingelheim
Johnson and Johnson
Colorcon

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Evogliptin

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Evogliptin?

Evogliptin is an investigational drug.

There have been 16 clinical trials for Evogliptin. The most recent clinical trial was a Phase 3 trial, which was initiated on April 12th 2019.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Liver Diseases. The leading clinical trial sponsors are Dong-A ST Co., Ltd., Samsung Medical Center, and Eurofarma Laboratorios S.A.

There are five US patents protecting this investigational drug and ninety-six international patents.

Recent Clinical Trials for Evogliptin
TitleSponsorPhase
The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis PatientsDong-A ST Co., Ltd.Phase 1
Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic ControlDong-A ST Co., Ltd.Phase 3
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver DiseasesDong-A ST Co., Ltd.Phase 4

See all Evogliptin clinical trials

Clinical Trial Summary for Evogliptin

Top disease conditions for Evogliptin
Top clinical trial sponsors for Evogliptin

See all Evogliptin clinical trials

US Patents for Evogliptin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Evogliptin   Start Trial Composition containing a DPP-IV inhibitor for preventing or treating renal diseases DONG-A ST Co., Ltd (Seoul, KR)   Start Trial
Evogliptin   Start Trial DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity Dong-A Pharm. Co., Ltd. (Seoul, KR)   Start Trial
Evogliptin   Start Trial Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients Dong-A Pharmaceutical Co. Ltd. (Seoul, KR)   Start Trial
Evogliptin   Start Trial Method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate Dong-A Pharmaceutical. Co., Ltd (Seoul, KR)   Start Trial
Evogliptin   Start Trial Method for preparing dipeptidyl peptidase-IV inhibitor and intermediate DONG-A PHARMACEUTICAL CO., LTD. (Seoul, KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Evogliptin

Drugname Country Document Number Estimated Expiration Related US Patent
Evogliptin Australia 2014299575 2033-06-26   Start Trial
Evogliptin Brazil 112015032410 2033-06-26   Start Trial
Evogliptin Canada 2916698 2033-06-26   Start Trial
Evogliptin China 105555275 2033-06-26   Start Trial
Evogliptin European Patent Office 3015106 2033-06-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Harvard Business School
Medtronic
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.